ADMA Adma Biologics, Inc.
Data as of close
Healthcare · Biological Products, (No Diagnostic Substances)
Adma Biologics, Inc. (ADMA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $2.5 billion. Shares last traded at $11.05, 45.9% below their 52-week high. Over the past year the stock is down 27.6%. ADMA trades at a price-to-earnings ratio of 14.65, below the Biological Products, (No Diagnostic Substances) median of 20.95. Net profit margin is 33.0%, above the peer median of -1.6%. Revenue grew 19.6% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $0.16 | 2026-08-05 |
| Q1 2026 | $0.19 | 2026-05-06 |
| Q4 2025 (derived) | $0.20 | 2026-02-25 |
| FY 2025 | $0.60 | 2026-02-25 |
| Q3 2025 | $0.15 | 2025-11-05 |
| Q2 2025 | $0.14 | 2025-08-06 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Biological Products, (No Diagnostic Substances) peers
ADMA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Data as of close
| AMGN | Amgen | $251.7B | 28.78 | 6.61 | 23.0% | -0.13% |
| GILD | Gilead Sciences | $211.3B | — | 6.82 | -12.5% | -0.23% |
| MRNA | Moderna | $88.2B | — | — | — | -0.12% |
| RVMD | Revolution Medicines, Inc. | $40.4B | — | — | — | -1.58% |
| BIIB | Biogen | $36.8B | 105.92 | 3.57 | 3.4% | -1.83% |
| EXEL | Exelixis, Inc. | $17.1B | 19.32 | 6.85 | 35.5% | +1.02% |
| NBIX | Neurocrine Biosciences Inc | $14.7B | 20.95 | 3.98 | 19.0% | -0.52% |
| HALO | Halozyme Therapeutics, Inc. | $14.6B | 35.38 | 8.80 | 24.9% | -1.50% |
| TECH | Bio-Techne | $11.4B | 62.76 | 9.39 | 15.0% | -0.03% |
| RGEN | Repligen Corp | $11.1B | — | 13.73 | -1.5% | -2.17% |
| QGEN | Qiagen N.V. | $10.9B | 25.70 | 5.22 | 20.3% | +0.33% |
| KYMR | Kymera Therapeutics, Inc. | $10.9B | — | — | — | +0.68% |
| PCVX | Vaxcyte, Inc. | $9.0B | — | — | — | -2.26% |
| KRYS | Krystal Biotech, Inc. | $8.8B | 38.95 | 18.66 | 47.9% | -10.76% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.